Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11C-YJH08 is a radiolabeled small molecule diagnostic agent used as a positron emission tomography (PET) tracer for imaging glucocorticoid receptor (GR) expression in vivo. It consists of the synthetic GR agonist YJH08 labeled with the positron-emitting isotope carbon C 11. The compound binds potently and selectively to the ligand-binding domain of GR, enabling noninvasive visualization and quantification of GR levels in tissues and tumors. This makes it useful for assessing altered GR expression and pharmacodynamics in cancer patients—particularly those with advanced malignant solid neoplasms or metastatic castration-resistant prostate cancer (mCRPC). The tracer has demonstrated high affinity for GR (Ki ~0.4 nM), rapid blood clearance, high tissue uptake including brain penetration, and specificity confirmed by competition studies. It is being developed as a companion diagnostic to guide therapy targeting the glucocorticoid receptor pathway[1][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 11C-YJH08.